AK120

DRUG6 trials

Sponsors

Akesobio Australia Pty Ltd, Akeso

Conditions

AsthmaAtopic Dermatitis

Phase 1

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic Dermatitis

CompletedNCT06035354

AkesoAtopic Dermatitis

Start: 2021-11-03End: 2024-06-21Updated: 2025-03-05

Phase 2

Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis

TerminatedNCT05048056

Akesobio Australia Pty LtdAtopic Dermatitis

Start: 2021-09-30End: 2023-05-17Updated: 2025-02-26

A Study to Evaluate the Efficacy and Safety of AK120 in the Treatment of Subjects With Moderate-to-severe Asthma

TerminatedNCT05155020

Start: 2022-02-11End: 2022-08-05Updated: 2022-10-12

A Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis

CompletedNCT06092762

AkesoAtopic Dermatitis

Start: 2023-11-06End: 2024-11-13Updated: 2024-11-25

A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis (AD)

Not yet recruitingNCT06756126

AkesoAtopic Dermatitis

Start: 2024-12-30End: 2025-06-30Target: 24Updated: 2025-01-01

Phase 3

A Phase III Study to Evaluate the Efficacy and Safety of AK120 in Patients With Moderate to Severe Atopic Dermatitis

RecruitingNCT06383468

AkesoAtopic Dermatitis

Start: 2024-04-30End: 2026-01-30Target: 420Updated: 2024-04-25